Coming Soon
We’re working on something special. Enter your email below for updates and to be the first to explore our new site when it goes live.
Packages
Seamless access to world-class GLP-1 treatments, luxury accommodations, and personalised care. Choose a package that suits your needs and experience effortless wellness in London.
Packages
Seamless access to world-class GLP-1 treatments, luxury accommodations, and personalised care. Choose a package that suits your needs and experience effortless wellness in London.
What is Wegovy?
Wegovy is a weight loss injection that can be an effective aid to weight-loss when used alongside a reduced-calorie diet and increased exercise. The weight loss drug contains the active ingredient semaglutide. Unlike other weight loss shots, Wegovy is injected once a week and can be used by adults with a body mass index (BMI) over 30. It can also be used by people with a BMI over 27 with weight-related conditions (such as high blood pressure or type 2 diabetes).
How to Take Wegovy
The Wegovy dose is increased every 4 weeks for 16 weeks. This means that patients take a 0.25mg once weekly dose for the first 4 weeks and gradually increase it until they reach the maintenance dose of 2.4 mg once weekly from week 17 onwards. This gradual increase is important because it minimises the risk of side effects. If side effects do occur, most will be experienced during the dose-escalation phase before improving.
Wegovy®(Semaglutide)
Wegovy is an injectable weight-loss medication for overweight adults or adults with obesity. It contains the active ingredient semaglutide, which mimics a naturally occurring hormone called glucagon-like peptide-1 (GLP-1). This hormone helps to regulate your blood sugar levels, and also sends signals to receptors in your brain that manage your appetite, allowing you to feel fuller for longer.
What's included?
•
Effective GLP-1 weight loss treatment
•
Weekly self-injection pen
•
Lose up to 15% of your weight
•
Supports healthy weight loss by reducing appetite and making your feel fuller
•
Ongoing Campaign Monitoring and Management
•
Up to 6 months medication available with a provided travel certificaifate
Clinical trials have shown that Wegovy treatment resulted in a statistically significant reduction in body weight compared to placebo after 68 weeks. One trial showed that people taking Wegovy had a mean change in body weight of 14.9% compared to 2.4% in the placebo group.
The results also showed that, after 68 weeks, 83.5% of patients lost 5% or more of their body weight. In the placebo group, 31.1% of patients lost 5% or more of their body weight. Another clinical trial also showed a statistically significant reduction in body weight vs placebo.
Mounjaro (Tirzepatide) is an injectable medicine used to help adults manage their weight. It works by acting on hormones that control appetite, helping to reduce hunger and make you feel fuller.
Summary
•
GLP-1 injectable pens
•
Most effective
•
Weekly self-injection
•
Makes you feel fuller and reduces cravings
•
Lose up to 20% of your body weight The most effective GLP-1
•
Up to 6 months medication available with a provided travel certificaifate
The dosage titration of the drug, is designed to minimise side effects. Starting with Mounjaro 2.5mg, and moving up through 5mg in 2.5mg increments, helps the body adjust to the drug's impact. Doing this gradual titration, will allow you to minimise side effects and get the most out of your treatment.
Mounjaro should be stored in the refrigerator at a temperature between 2°C and 8°C. If necessary, you can keep it outside the fridge for up to 30 days, as long as the temperature stays below 30°C. After 30 days out of the fridge, you’ll need to throw it away.
What is Mounjaro?
Mounjaro is a highly effective, UK licensed weight loss treatment. It has been shown in clinical trials to help achieve up to 23% body weight loss. It is the latest GLP-1 weight loss injection, and is used for people with a body mass index (BMI) over 30. It can also be prescribed for patients with a BMI of 27+ and a weight-related medical condition, such as high blood pressure or cholesterol.
It contains the drug tirzepatide and is a registered trademark of Eli Lilly.
It is known as Zepbound in the US, but launched in the UK under the brand name Mounjaro.